Professor Chi-leung CHIANG

DR CHI-LEUNG CHIANG

Clinical Assistant Professor

  • MBChB (CUHK), FRCR , FHKCR, FHKAM (Radiology), PDip Epidemiology and Biostatistics (CUHK)
phone ---
email chiangcl@hku.hk
email HKU Scholars Hub
email http://orcid.org/0000-0002-9836-6478
Short Biography
Prof. Chiang graduated from the Chinese University of Hong Kong and received his fellowship in Clinical Oncology in 2012. He has received overseas training in stereotactic body radiotherapy and brachytherapy in John Hopkins Hospital, Princess Margaret Hospital, and Jewish General Hospital. He is currently the Clinical Assistant Professor in the Department of Clinical Oncology, the University of Hong Kong and Deputy Chief of Service, Clinical Oncology Center, University of Hong Kong-Shenzhen Hospital.

His expertise includes stereotactic body radiotherapy of liver and pancreatic cancer, and rectal brachytherapy. He has published peer-review journals and presented in overseas conferences. He is also the principal investigator of several ongoing prospective trials including, Sequential transarterial chemoembolization and stereotactic radiotherapy followed by Immunotherapy for downstaging hepatocellular carcinoma for hepatectomy (START-FIT trial) and Asian multi-center prospective phase II trial of external radiotherapy plus high dose rate brachytherapy in medically inoperable rectal cancer patients.
Research Interests
  1. Liver, pancreatic, colorectal, and nasopharyngeal cancer
  2. Stereotactic radiotherapy and brachytherapy
  3. Combined immunotherapy and radiotherapy
Grant Funding

Competitie Grants as Principal Investigator:  

  1. Health and Medical Research Fund (HMRF) 2016: Cost Effectiveness of Anti-EGFR Antibodies as First Line Treatment in RAS Wild Type Metastatic Colorectal Cancer in Hong Kong (Amount HK $99,627)
  2. Li Shu Pui Medical Foundation Research Grants 2017: Clinical Validation of Genomic Adjusted Radiation Dose (GARD) in Nasopharyngeal Carcinoma (NPC) (Amount HK$1,453,000)
  3. Health and Medical Research Fund (HMRF) 2017: Radiosensitivity index (RSI) as predictive biomarker for radiotherapy de-intensification in nasopharyngeal cancer (NPC) (Amount HK $1,499,916)
Selected Publications
  1. CHM Ho, CL Chiang, (co-first and corresponding author), FAS Lee, et al. Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT). Oncotarget 2018 Jun 22;9(48): 28818-28829.
  2. CL Chiang, MHK Chan, CSY Yeung, et al. Stereotactic Body Radiotherapy (SBRT) and Trans-arterial Chemoembolization (TACE) as Initial Treatment in BCLC stage B-C Hepatocellular Carcinoma (HCC). Strahlenther Onkol. 2019 Mar;195(3):254-264.
  3. TCL Wong, CL Chiang, AS Lee, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma patients: a propensity score matched analysis. Surgical Oncology 2019 March; (28): 228-235.
  4. KH Chan, CL Chiang, WK Leung, et al. Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas. PLoS One 2017 Apr 6;12(4):e0174929.
  5. Chan MK, Lee V, Chiang CL, et al. Lipiodol versus Diaphragm in 4D-CBCT-guided Stereotactic Radiotherapy of Hepatocellular Carcinoma. Strahlentherapie und Onkologie. Feb 2016, 192(2): 92-101.
  6. Lee AS, Zee B, Cheung FY, Kwong P, Cheng A, Chiang CL, Leung KC, Siu S, Lee C, Lai M, Kwok C, Chong M, J Jolivet, Tung Y. Randomized Phase II study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC). American Journal of Clinical Oncology 2016 Dec; 39 (6): 609-613.
  7. SF Lee, CL Chiang (corresponding author), FAS Lee, YW Wong, CM Poon, FCS Wong, SY Tung. Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients. 2018 Sep;117(9):825-832.
  8. CL Chiang, HC Choi, KO Lam, et al. Real-World Treatment Patterns and Outcomes in Refractory Metastatic Colorectal Cancer. Asia Pac J Clin Oncol. 2019 Mar 19. doi: 10.1111/ajco.13114. [Epub ahead of print].
Key Offices
  • Deputy Chief of Service, Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital
  • Treasurer and Council Member, Hong Kong Stereotactic Body Radiotherapy Society
  • Executive Committee Member, Pan-Pearl River Area Radiation Therapy Oncology Group (PPRA-RTOG)